Form 4: Vertex Pharmaceuticals EVP, COO Acquires Shares Following Performance Goal Attainment

Stuart A. Arbuckle, EVP and COO of Vertex Pharmaceuticals, reports acquisition of shares related to performance stock unit awards.

Summary

• Stuart A. Arbuckle, the EVP and COO of Vertex Pharmaceuticals, has reported changes in beneficial ownership of the company's stock.
• On February 4, 2025, Arbuckle acquired 14,624 shares of common stock related to a performance stock unit award granted on February 1, 2022, at a price of $0 per share, bringing his direct holdings to 64,315 shares.
• He also acquired 8,448 shares of common stock related to a performance stock unit award granted on February 7, 2024, at a price of $0 per share, increasing his direct holdings to 72,763 shares.
• These acquisitions are due to the attainment of performance goals certified by the company's management development and compensation committee on February 4, 2025.
• Arbuckle also holds 140 shares of common stock indirectly through a 401(k) plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the vesting of performance stock units indicates that the company has achieved certain performance goals. This suggests that the company is performing well, which is generally viewed favorably by investors.

Positives

• The attainment of performance goals leading to the vesting of performance stock units suggests positive performance by the company and its executives.
• The increased holdings of company stock by a key executive like the COO can be seen as a sign of confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of performance stock units suggests an expectation of continued performance that meets pre-defined goals.

Industry Context

Executive stock ownership changes are common in the pharmaceutical industry and are often tied to performance-based compensation plans. These plans are designed to align executive interests with those of shareholders and incentivize value creation.

Comparison to Industry Standards

• Performance-based equity compensation is a standard practice among publicly traded pharmaceutical companies.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize performance stock units (PSUs) as part of their executive compensation packages.
• The specific performance metrics and vesting schedules vary by company, but the underlying principle of linking executive pay to company performance is consistent across the industry.

Stakeholder Impact

• Shareholders may view the vesting of performance stock units positively, as it suggests that the company is meeting its performance targets.
• Employees may be motivated by the company's achievement of performance goals, as it can lead to increased compensation and job security.

Next Steps

• The 14,624 shares from the 2022 award will vest on February 26, 2025.
• The 8,448 shares from the 2024 award will vest in installments beginning on February 17, 2025.

Key Dates